Monday, November 9, 2020
Monday, August 10, 2020
While the president was demanding a fourth debate with his challenger, an opinion piece in The New York Times suggested that debates be scrapped altogether. Yes, the debates have certainly devolved over the years but this is a classic “throw the baby out with the bathwater” reaction. Let’s fix them instead. Here are three changes to elevate the debates and increase their value to the public:
1. Ditch the audience. In her NYT piece, Elizabeth Drew wrote that debates were less about conveying a vision or a plan than they were about upstaging the opponent. “Points went to snappy comebacks and one-liners. Witty remarks drew laughs from the audience and got repeated for days and remembered for years,” she said. She’s not wrong, of course. But it’s the debate format that has helped to create the reality TV atmosphere. The candidates have been playing to the audience; they look for applause or a laugh. Let’s get serious and let’s remove the audience. The point might be made moot because of the pandemic this year but the editorial board of The Washington Post recently endorsed this idea, calling the debates “quip contests.” We’ll gain time, engagement, and potentially more substantive responses.
2. Level the field. I mean this literally. The candidates should be seated, anchored to their chairs. The freewheeling Town Hall format, where the candidates roam the stage, should be banned. In 2016, candidate Trump tried to intimidate Secretary Clinton when he alternated between standing and pacing back-and-forth behind her. Clinton said he was breathing down her neck, which made her feel "incredibly uncomfortable." Politico magazine called it "the ugliest debate ever seen." Pressing a physical advantage – bullying – must not be allowed. And having the candidates seated will also help mitigate any height discrimination, or “heightism,” where taller people are perceived to be stronger, and better leaders.
3. Check the facts. A consequence of our glorious First Amendment is that political speech is highly protected – essentially any half-truth or lie may be told. While there are plenty of post-debate analyses, it’s too late. Many viewers tune-out after the practiced smiles and forced handshakes. And our brains tend to cling to misinformation even after it's been refuted. We need real time (or near real time) fact checking. If IBM's Watson computer can win at Jeopardy!, why can't we get an indication of veracity while the debate is still in progress? Let’s use technology to help the experts sift through speech transcripts and testimony; almanacs and atlases; laws, regulations and policy statements; credible survey data, and non-partisan news articles, journals, and research reports. Let’s help ensure the public gets the facts and not the flimflam.
While we’re more polarized than ever and fewer people are undecided, more information, more opportunity for side-by-side comparison, is still crucial to the democratic process. In a society that’s increasingly stressed by the health and economic consequences of COVID-19, systemic racism, and so many other issues, political discussion can be dispiriting, infuriating, and sometimes incendiary. But, as Ray Bradbury wrote in Fahrenheit 451, “If you don't want a man unhappy politically, don't give him two sides to a question to worry him; give him one. Better yet, give him none.”
Between blog posts, I invite you to follow me @pauloestreicher.
Thursday, May 28, 2020
I was sad to read of his passing but this is not an obituary covering all the details of his dynamic life; it’s a brief reflection starting when we met in 1988. I was the chief representative to the HIV/AIDS and oncology patient communities at drug giant Hoffmann-La Roche and he was on the other side of a conference room table. His first comment to me was, “Bristol-Myers met us in a nicer hotel.”
The year before, I joined the company’s Public Affairs department from the R&D group. There was a need for someone with a technical background to help explain what was coming out of the labs to the general public. I landed in the role and immediately found myself in the middle of history. Roche was one of only three companies at the time that had a late-stage anti-HIV drug development program. Burroughs Wellcome (now part of Glaxo) had the first marketed product, Retrovir®/AZT. Bristol-Myers (now Bristol-Myers Squibb) and Roche had retroviral analogs in the pipeline.
Burroughs Wellcome was reviled by the AIDS community Larry helped to organize. Drug prices were high and communication from the company was absent. There were no best practices, no case studies on how to communicate with patients. It simply wasn’t done. Companies would inform the “learned intermediary” – the physician – and he or she would communicate with the patient.
Today, there’s at least one patient advocacy organization for any given disease. There were only a handful of AIDS groups in those days. Larry and others paved the way for all the rest.
Bristol-Myers decided to meet with the AIDS groups and I began my campaign to convince Roche management to do the same. I remember making a presentation to the Executive Committee and quoted Lincoln: “As our case is new, so we must think anew, and act anew.” It wasn’t the easiest sell. But people realized there were both ethical and business considerations at play – many of the activists were patients trying to save their own lives, and they were phenomenally organized and well informed. The potential benefits of hearing the patients’ point of view and adjusting our own plans were new and valuable concepts.
A letter from Larry’s organization, ACT UP (the AIDS Coalition to Unleash Power) was the catalyst for our first meeting. He once said, “If you write a calm letter and fax it to nobody, it sinks like a brick in the Hudson.” The demands in the letter were copied to a long list of top-tier news media, members of Congress, AIDS activists, and health care policy makers. I wrote back, explained our research initiative, agreed to meet, and copied back the entire list.
Then, my phone rang. “What are you doing writing back to all my constituents?,” he barked. I said, “They’re our constituents, too.”
That was a pivotal moment. Yes, I gained some respect by coming right back at him but the truly important piece was that first step we took into a common ground. Our constituency was their constituency and everyone wanted new, effective medications in the hands of patients as soon as possible. The two “sides” worked to expand access to experimental therapeutics, enroll patients into clinical trials, support NIH funding, and lobby for FDA reform to speed drug reviews and approvals.
The world was changing. The normal course of business – the normal course of life – was disrupted. But progress was made – advancements in understanding and equality, as well as advancements in medical science.
Larry was called a troublemaker and much worse. But at least there was talk back then and a respect for science. It’s worth noting that ACT UP’s slogan was Silence = Death. With COVID-19, I’m afraid Silence has been replaced by Division and Ignorance. Maybe a little Larry Kramer-style agitation wouldn’t be such a bad thing to get people think about the state of our society and the status of our health care system.
Between blog posts, I invite you to follow me @pauloestreicher.